French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3%
French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3% compared with FFr 1.12 billion ($182.3 million) in 1997. But the companys bottom line swung into the red, with Guerbet recording a net loss of $10.8 million, compared with a net profit of $10.7 million the prior year.
Guerbet embarked on a stringent restructuring program in 1998 to counter increased competition and price pressures in its primary markets, which are mainly x-ray contrast media. The restructuring included a 10% workforce cut. Guerbet said that it expects to return to profitability in 1999.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.